Rigel highlights new GAVRETO® (pralsetinib) data across RET fusion-positive cancers in oral and poster presentations at ESMO Congress 2026

Summary

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-reported quality of...